A systematic review published online in the Journal of the American Academy of Dermatology on October 17, 2026 examines Kaposi sarcoma developing during treatment with Janus kinase inhibitors, framing the malignancy as an emerging safety signal for a drug class now embedded across dermatology practice.

Mohammed Shanshal and Jessica Chen, the review's authors, compiled reported cases of Kaposi sarcoma arising in patients receiving JAK inhibition. The paper's central question is simple. Does blocking JAK-mediated signaling create conditions in which Kaposi sarcoma — a vascular tumor driven by human herpesvirus 8 — can take hold in skin?

Why does this matter for dermatologists?

JAK inhibitors have moved rapidly into the dermatologic arsenal. Oral agents in this class now treat psoriasis, atopic dermatitis and other inflammatory diseases, and prescriptions continue to climb. More exposure means more rare events surface. That is the arithmetic behind any emerging signal.

Kaposi sarcoma sits at the intersection of immunosuppression and viral oncology. HHV-8-infected endothelial cells proliferate when immune surveillance falters, which is why the tumor classically appears in HIV/AIDS and in transplant recipients on immunosuppressive regimens. A drug class that dampens cytokine signaling plausibly belongs on that list of triggers. The review asks whether the accumulating case reports justify that placement.

Dermatologists are often the first clinicians to see Kaposi sarcoma. The lesions typically present as violaceous patches, plaques or nodules on skin, and a biopsy confirms the diagnosis. Any therapy that increases the odds of that presentation deserves a slot in pre-treatment counseling and post-treatment monitoring.

What does a systematic review add?

Individual case reports are anecdotes. A systematic review gathers them under one method, searching the literature comprehensively and appraising what the cases share. Shanshal and Chen used that structure to characterize the emerging signal: which JAK inhibitors were involved, what the patients looked like, and how the tumors behaved after the drug was stopped or continued.

That last point carries real clinical weight. In drug-associated Kaposi sarcoma, withdrawal of the offending agent sometimes leads to lesion regression, which strengthens the causal argument. The review's value lies in aggregating those individual outcomes into a pattern a single report cannot show.

Without numbers from the source text, the honest framing is this: the review defines the signal rather than quantifying a risk. That distinction matters. A systematic review of case reports can establish plausibility and alertness. It cannot establish incidence.

How should clinicians respond?

The practical takeaway runs along three lines:

• History before prescribing. HHV-8 serostatus is rarely checked in routine dermatology, but patients from endemic regions or with prior Kaposi sarcoma warrant consideration before starting a JAK inhibitor.
• Skin surveillance during therapy. New violaceous lesions in a patient on JAK inhibition should trigger biopsy rather than a watch-and-wait approach.
• Reporting new cases. Signals like this one grow only when clinicians publish what they see.

None of this argues against JAK inhibitors. It argues for knowing the tail of the risk distribution, not just its center. Every immunomodulatory class has carried its own malignancy conversation, and this review extends that conversation to JAK blockade.

What comes next?

Shanshal and Chen's review arrives as JAK inhibitor prescribing widens in dermatology, and it will likely inform label discussions, monitoring guidance and shared decision-making conversations in the clinic. Pharmacovigilance databases and post-marketing studies should now test whether the case-level signal holds at population scale.